The first step for treating patients with endothelial dysfunction and hypoperfusion (identified by reduced CBF on ASL-MRI and elevated endothelial markers) involves cilostazol or PDE5 inhibitors because these medications directly impact blood vessel function [163]. Here, PDE5A is linked to endothelial dysfunction.